Sacubitril-Valsartan: A Cost-Effective Solution for Heart Failure Management

By Staff Writer

October 7, 2023

A New Class IA Recommendation for Heart Failure Treatment

Heart failure, a major cause of hospital admissions in the U.S., comes with high morbidity, mortality, and financial costs. Recent advances in pharmacotherapy for heart failure with reduced ejection fraction (HFrEF) have given rise to new disease-modifying therapies. One such novel angiotensin receptor neprilysin inhibitor (ARNI) is sacubitril-valsartan.

The PARADIGM-HF clinical trial found that sacubitril-valsartan reduced the risk of cardiovascular death or hospitalization due to heart failure (HF), among ambulatory patients with an HFrEF of 40% or less. This makes it a highly cost-effective treatment option.

Broadening the Scope of Sacubitril-Valsartan

In February 2021, the U.S. Food and Drug Administration expanded the labelling of sacubitril-valsartan to include all adult patients with chronic HF. This decision was based on the understanding that the benefits are most evident in patients with left ventricular ejection fraction (LVEF) below normal. However, the upper bound of below-normal EF is not well defined.

A recent economic evaluation of treatment with sacubitril-valsartan vs renin-angiotensin system inhibitors (RASis) in patients with HF across a broader range of EFs found the treatment to be of high economic value for patients with EF≤50%. It showed intermediate value up to an EF of 60% or less before accounting for any price concessions that payers may receive.

Commentary from Cohen at al., mentioned that the economic value of sacubitril-valsartan is comparable to sodium-glucose cotransporter 2 inhibitors (SGLT2is). Both are dependent on drug price. SGLT2is were estimated to be intermediate value costing $126 500 and $139 000 per quality-adjusted life year in those with LVEFs of 40% to 49% and 50% to 59%, respectively. However, these analyses do not consider the affordability of the medications for individuals. Economic assessments of these novel medications suggest they could add billions to US healthcare spending. Without efforts to lower drug prices, the use of costly, intermediate- to low-value care may be reinforced.

Conclusion
Sacubitril-valsartan increases quality-adjusted life years (QALYs) at an incremental cost-effectiveness ratio consistent with high economic value for patients inclusive of reduced and mildly reduced EFs (≤50%). The data analysis of 13,264 total patients showed that for those with EFs of 60% or less, sacubitril-valsartan could potentially add 0.53 quality-adjusted life-years (QALYs). This would come at an incremental lifetime cost of $40,892 compared to RASi, resulting in an ICER of $76,852 per QALY. Therefore, it is estimated to be of at least intermediate value when using the current undiscounted wholesale acquisition cost price across a broad HF population with EFs below normal, when below normal is defined as an EF of 60% or less.

Reference url

Recent Posts

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

tislelizumab NSCLC treatment
        

Early Benefit Assessment of Tislelizumab NSCLC Treatment: Insights and Implications

🧐 How is the evolving treatment landscape for NSCLC affecting patient access to tislelizumab?

The German Federal Joint Committee (G-BA) has launched an early benefit assessment for tislelizumab as a second-line treatment for adults with advanced NSCLC. This assessment notably focuses on PD-L1 negative patients and highlights the need for additional data to substantiate its value amidst a shifting emphasis on first-line immunotherapy.

Explore the nuances of this assessment and its implications for future research and market access in the full article.

#SyenzaNews #oncology #MarketAccess

colorectal cancer screening
    

Advances in Colorectal Cancer Screening: Access and Cost

🚀 Is blood-based screening redefining colorectal cancer detection?

The Shield blood test offers a non-invasive alternative to colonoscopy—boosting screening uptake, but raising questions around effectiveness and value.

🔍 Discover how this innovation could reshape patient care, payer strategy, and health system costs.

#SyenzaNews #HealthcareInnovation #CostEffectiveness #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.